Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319663181> ?p ?o ?g. }
- W4319663181 endingPage "730" @default.
- W4319663181 startingPage "718" @default.
- W4319663181 abstract "IntroductionPatient selection for checkpoint inhibitor immunotherapy is currently guided by programmed death-ligand 1 (PD-L1) expression obtained from immunohistochemical staining of tumor tissue samples. This approach is susceptible to limitations resulting from the dynamic and heterogeneous nature of cancer cells and the invasiveness of the tissue sampling procedure. To address these challenges, we developed a novel computed tomography (CT) radiomic-based signature for predicting disease response in patients with NSCLC undergoing programmed cell death protein 1 (PD-1) or PD-L1 checkpoint inhibitor immunotherapy.MethodsThis retrospective study comprises a total of 194 patients with suitable CT scans out of 340. Using the radiomic features computed from segmented tumors on a discovery set of 85 contrast-enhanced chest CTs of patients diagnosed with having NSCLC and their CD274 count, RNA expression of the protein-encoding gene for PD-L1, as the response vector, we developed a composite radiomic signature, lung cancer immunotherapy—radiomics prediction vector (LCI-RPV). This was validated in two independent testing cohorts of 66 and 43 patients with NSCLC treated with PD-1 or PD-L1 inhibition immunotherapy, respectively.ResultsLCI-RPV predicted PD-L1 positivity in both NSCLC testing cohorts (area under the curve [AUC] = 0.70, 95% confidence interval [CI]: 0.57–0.84 and AUC = 0.70, 95% CI: 0.46–0.94). In one cohort, it also demonstrated good prediction of cases with high PD-L1 expression exceeding key treatment thresholds (>50%: AUC = 0.72, 95% CI: 0.59–0.85 and >90%: AUC = 0.66, 95% CI: 0.45–0.88), the tumor’s objective response to treatment at 3 months (AUC = 0.68, 95% CI: 0.52–0.85), and pneumonitis occurrence (AUC = 0.64, 95% CI: 0.48–0.80). LCI-RPV achieved statistically significant stratification of the patients into a high- and low-risk survival group (hazard ratio = 2.26, 95% CI: 1.21–4.24, p = 0.011 and hazard ratio = 2.45, 95% CI: 1.07–5.65, p = 0.035).ConclusionsA CT radiomics-based signature developed from response vector CD274 can aid in evaluating patients’ suitability for PD-1 or PD-L1 checkpoint inhibitor immunotherapy in NSCLC." @default.
- W4319663181 created "2023-02-10" @default.
- W4319663181 creator A5002832904 @default.
- W4319663181 creator A5009737345 @default.
- W4319663181 creator A5014610135 @default.
- W4319663181 creator A5023266777 @default.
- W4319663181 creator A5029495631 @default.
- W4319663181 creator A5054775841 @default.
- W4319663181 creator A5060954139 @default.
- W4319663181 creator A5063076993 @default.
- W4319663181 creator A5071080479 @default.
- W4319663181 creator A5077604000 @default.
- W4319663181 date "2023-06-01" @default.
- W4319663181 modified "2023-10-16" @default.
- W4319663181 title "A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC" @default.
- W4319663181 cites W2103004421 @default.
- W4319663181 cites W2104347254 @default.
- W4319663181 cites W2149496200 @default.
- W4319663181 cites W2210073947 @default.
- W4319663181 cites W2275877493 @default.
- W4319663181 cites W2329674354 @default.
- W4319663181 cites W2398056625 @default.
- W4319663181 cites W2527905628 @default.
- W4319663181 cites W2566809924 @default.
- W4319663181 cites W2592144107 @default.
- W4319663181 cites W2746276968 @default.
- W4319663181 cites W2759538409 @default.
- W4319663181 cites W2763355946 @default.
- W4319663181 cites W2766233251 @default.
- W4319663181 cites W2885326465 @default.
- W4319663181 cites W2896246551 @default.
- W4319663181 cites W2913823430 @default.
- W4319663181 cites W2925446385 @default.
- W4319663181 cites W2945974095 @default.
- W4319663181 cites W2971041600 @default.
- W4319663181 cites W2976744492 @default.
- W4319663181 cites W2981320816 @default.
- W4319663181 cites W2983529249 @default.
- W4319663181 cites W2995123342 @default.
- W4319663181 cites W2997277554 @default.
- W4319663181 cites W2998789541 @default.
- W4319663181 cites W3000652717 @default.
- W4319663181 cites W3009724004 @default.
- W4319663181 cites W3093156106 @default.
- W4319663181 cites W3118361511 @default.
- W4319663181 cites W3124556679 @default.
- W4319663181 cites W3124571455 @default.
- W4319663181 cites W3162422809 @default.
- W4319663181 cites W4205957126 @default.
- W4319663181 cites W4221030130 @default.
- W4319663181 doi "https://doi.org/10.1016/j.jtho.2023.01.089" @default.
- W4319663181 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36773776" @default.
- W4319663181 hasPublicationYear "2023" @default.
- W4319663181 type Work @default.
- W4319663181 citedByCount "4" @default.
- W4319663181 countsByYear W43196631812023 @default.
- W4319663181 crossrefType "journal-article" @default.
- W4319663181 hasAuthorship W4319663181A5002832904 @default.
- W4319663181 hasAuthorship W4319663181A5009737345 @default.
- W4319663181 hasAuthorship W4319663181A5014610135 @default.
- W4319663181 hasAuthorship W4319663181A5023266777 @default.
- W4319663181 hasAuthorship W4319663181A5029495631 @default.
- W4319663181 hasAuthorship W4319663181A5054775841 @default.
- W4319663181 hasAuthorship W4319663181A5060954139 @default.
- W4319663181 hasAuthorship W4319663181A5063076993 @default.
- W4319663181 hasAuthorship W4319663181A5071080479 @default.
- W4319663181 hasAuthorship W4319663181A5077604000 @default.
- W4319663181 hasBestOaLocation W43196631811 @default.
- W4319663181 hasConcept C121608353 @default.
- W4319663181 hasConcept C126322002 @default.
- W4319663181 hasConcept C126838900 @default.
- W4319663181 hasConcept C143998085 @default.
- W4319663181 hasConcept C163500349 @default.
- W4319663181 hasConcept C167135981 @default.
- W4319663181 hasConcept C185592680 @default.
- W4319663181 hasConcept C204232928 @default.
- W4319663181 hasConcept C2776256026 @default.
- W4319663181 hasConcept C2777701055 @default.
- W4319663181 hasConcept C2778559731 @default.
- W4319663181 hasConcept C2781053074 @default.
- W4319663181 hasConcept C2781197716 @default.
- W4319663181 hasConcept C44249647 @default.
- W4319663181 hasConcept C55493867 @default.
- W4319663181 hasConcept C58471807 @default.
- W4319663181 hasConcept C71924100 @default.
- W4319663181 hasConceptScore W4319663181C121608353 @default.
- W4319663181 hasConceptScore W4319663181C126322002 @default.
- W4319663181 hasConceptScore W4319663181C126838900 @default.
- W4319663181 hasConceptScore W4319663181C143998085 @default.
- W4319663181 hasConceptScore W4319663181C163500349 @default.
- W4319663181 hasConceptScore W4319663181C167135981 @default.
- W4319663181 hasConceptScore W4319663181C185592680 @default.
- W4319663181 hasConceptScore W4319663181C204232928 @default.
- W4319663181 hasConceptScore W4319663181C2776256026 @default.
- W4319663181 hasConceptScore W4319663181C2777701055 @default.
- W4319663181 hasConceptScore W4319663181C2778559731 @default.
- W4319663181 hasConceptScore W4319663181C2781053074 @default.
- W4319663181 hasConceptScore W4319663181C2781197716 @default.